

Accepted Manuscript


Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 Trial

Ilaria Cavallari, Christian T. Ruff, Francesco Nordio, Naveen Deenadayalu, Minggao Shi, Hans Lanz, Howard Rutman, Michele F. Mercuri, Elliott M. Antman, Eugene Braunwald, Robert P. Giugliano

PII: S0167-5273(17)35262-2
DOI: doi:[10.1016/j.ijcard.2018.01.065](https://doi.org/10.1016/j.ijcard.2018.01.065)
Reference: IJCA 25929

To appear in: *International Journal of Cardiology*

Received date: 24 August 2017
Revised date: 9 January 2018
Accepted date: 15 January 2018



Please cite this article as: Cavallari Ilaria, Ruff Christian T., Nordio Francesco, Deenadayalu Naveen, Shi Minggao, Lanz Hans, Rutman Howard, Mercuri Michele F., Antman Elliott M., Braunwald Eugene, Giugliano Robert P., Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 Trial, *International Journal of Cardiology* (2018), doi:[10.1016/j.ijcard.2018.01.065](https://doi.org/10.1016/j.ijcard.2018.01.065)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Clinical Events after Interruption of Anticoagulation in Patients with Atrial Fibrillation: An
Analysis from the ENGAGE AF-TIMI 48 Trial**

Ilaria Cavallari^{1,2}, MD, Christian T. Ruff¹, MD, MPH, Francesco Nordio¹, PhD,
Naveen Deenadayalu¹, MPH, Minggao Shi³, PhD, Hans Lanz³, MD, Howard Rutman⁴, MD,
Michele F. Mercuri³, MD, PhD, Elliott M. Antman¹, MD, Eugene Braunwald¹, MD,
Robert P. Giugliano¹, MD, SM

¹TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; ²Department of Cardiovascular Science, Campus Bio-Medico University of Rome, Rome, Italy; ³Daiichi Sankyo Pharma Development, Edison, NJ; ⁴Daiichi Sankyo Inc, Parsippany, NJ

All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation

Text word count: 2676

Key-words: Oral Anticoagulation; Interruption; Atrial Fibrillation; Stroke.

ENGAGE AF-TIMI 48 trial was supported by a research grant from Daiichi Sankyo Pharma Development to the Brigham and Women's Hospital.

Corresponding author:

Robert P. Giugliano, MD, SM

TIMI Study Group

60 Fenwood Road, 7th floor – Suite 7022

Boston, MA 02115

Phone: 617-278-0181, FAX: 617-264-5130

Email: rgiugliano@partners.org

Download English Version:

<https://daneshyari.com/en/article/8662318>

Download Persian Version:

<https://daneshyari.com/article/8662318>

[Daneshyari.com](https://daneshyari.com)